Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly

被引:13
|
作者
Madsen, Michael [1 ]
Fisker, Sanne [1 ]
Feldt-Rasmussen, Ulla [2 ]
Andreassen, Mikkel [3 ]
Kristensen, Lars Ostergaard [3 ]
Orskov, Hans [1 ]
Jorgensen, Jens Otto L. [1 ]
机构
[1] Aarhus Univ Hosp, Dept Endocrinol & Internal Med MEA, DK-8000 Aarhus C, Denmark
[2] Natl Univ Hosp, Dept Med Endocrinol, Copenhagen, Denmark
[3] Univ Copenhagen, Herlev Hosp, Dept Endocrinol, DK-2730 Herlev, Denmark
关键词
RECEPTOR ANTAGONIST PEGVISOMANT; LONG-TERM TREATMENT; SOMATOSTATIN ANALOG; FACTOR-I; PREVIOUS RADIOTHERAPY; PATIENTS RESISTANT; TUMOR VOLUME; GH; SERUM; COMBINATION;
D O I
10.1111/cen.12239
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate whether pegvisomant treatment in acromegaly induces gradual elevations in endogenous serum growth hormone (GH) levels and whether serum pegvisomant levels predict the therapeutic outcome. Patients and Methods Seventeen patients (6 women), mean age 46.3 years (range: 23.2-76.2), were studied. For each patient, four hospital visits were identified including 'active disease' (no treatment) and last follow-up. At each visit, 12 blood samples were drawn during 3h including an oral glucose tolerance test (OGTT). Eight patients received a somatostatin analogue in addition to pegvisomant on the last visit. Results Median (range) pegvisomant doses (mg/day) were 10 (10-10), 15 (10-15) and 15 (10-15) at visits 2, 3 and 4, respectively, and the mean duration of pegvisomant treatment was 17.5 +/- 3.2 (SEM) months. Serum IGF-I changed significantly during the treatment period with the highest level at baseline and lowest levels at visits 3 and 4. GH levels increased in a dose-dependent manner during pegvisomant treatment and decreased at visit 4. Changes in IGF-I levels correlated negatively with changes in serum pegvisomant levels between visits. Serum pegvisomant at each visit correlated with baseline growth hormone levels, whereas no associations between serum pegvisomant and either dose, gender, age or body weight were found. Conclusions (1) Serum GH levels increased initially, but remained stable during prolonged pegvisomant treatment in patients with acromegaly, (2) serum pegvisomant levels predicted the reduction in serum IGF-I during treatment and (3) the interindividual variation in serum pegvisomant levels seems not predicted by either age, gender or body composition.
引用
收藏
页码:92 / 100
页数:9
相关论文
共 50 条
  • [41] Treatment of acromegaly with pegvisomant during pregnancy: Maternal and fetal effects
    Brian, Susan Riddle
    Bidlingmaier, Martin
    Wajnrajch, Michael P.
    Weinzimer, Stuart A.
    Inzucchi, Silvio E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09): : 3374 - 3377
  • [42] What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?
    Muhammad, A.
    van der Lely, A. J.
    O'Connor, R. D.
    Delhanty, P. J.
    Dal, J.
    Dallenga, A. H.
    Feelders, R. A.
    Janssen, J. A. M. J. L.
    Jorgensen, J. O. L.
    Neggers, S. J. C. M. M.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 174 (05) : 663 - 667
  • [43] Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study
    Camara, Rosa
    Venegas, Eva
    Antonio Garcia-Arnes, Juan
    Cordido, Fernando
    Aller, Javier
    Luz Samaniego, M.
    Mir, Nuria
    Sanchez-Cenizo, Laura
    PITUITARY, 2019, 22 (02) : 137 - 145
  • [44] Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY
    Chanson, Philippe
    Brue, Thierry
    Delemer, Brigitte
    Caron, Philippe
    Borson-Chazot, Francoise
    Zouater, Hichem
    ANNALES D ENDOCRINOLOGIE, 2015, 76 (06) : 664 - 670
  • [45] Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
    Brue, Thierry
    Lindberg, Anders
    van der Lely, Aart Jan
    Akerblad, Ann Charlotte
    Koltowska-Haeggstrom, Maria
    Gomez, Roy
    Droste, Michael
    Hey-Hadavi, Judith
    Strasburger, Christian J.
    Camacho-Hubner, Cecilia
    ENDOCRINE, 2019, 63 (03) : 563 - 572
  • [46] Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
    Emmanuelle Kuhn
    Philippe Caron
    Brigitte Delemer
    Isabelle Raingeard
    Hervé Lefebvre
    Gérald Raverot
    Christine Cortet-Rudelli
    Rachel Desailloud
    Clementine Geffroy
    Robin Henocque
    Yves Brault
    Thierry Brue
    Philippe Chanson
    Endocrine, 2021, 71 : 265 - 265
  • [47] Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study
    Rosa Cámara
    Eva Venegas
    Juan Antonio García-Arnés
    Fernando Cordido
    Javier Aller
    M. Luz Samaniego
    Nuria Mir
    Laura Sánchez-Cenizo
    Pituitary, 2019, 22 : 137 - 145
  • [48] Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
    Thierry Brue
    Anders Lindberg
    Aart Jan van der Lely
    Ann Charlotte Akerblad
    Maria Koltowska-Häggström
    Roy Gomez
    Michael Droste
    Judith Hey-Hadavi
    Christian J Strasburger
    Cecilia Camacho-Hübner
    Endocrine, 2019, 63 : 563 - 572
  • [49] Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
    Emmanuelle Kuhn
    Philippe Caron
    Brigitte Delemer
    Isabelle Raingeard
    Hervé Lefebvre
    Gérald Raverot
    Christine Cortet-Rudelli
    Rachel Desailloud
    Clementine Geffroy
    Robin Henocque
    Yves Brault
    Thierry Brue
    Philippe Chanson
    Endocrine, 2021, 71 : 158 - 167
  • [50] Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly
    Kuker, Adriana P.
    Shen, Wei
    Jin, Zhezhen
    Singh, Simran
    Chen, Jun
    Bruce, Jeffrey N.
    Freda, Pamela U.
    JOURNAL OF THE ENDOCRINE SOCIETY, 2021, 5 (03)